Fintel reports that on October 9, 2023, JP Morgan maintained coverage of Progyny (NASDAQ:PGNY) with a Overweight recommendation.
Analyst Price Forecast Suggests 48.43% Upside
As of October 5, 2023, the average one-year price target for Progyny is 50.13. The forecasts range from a low of 46.46 to a high of $54.60. The average price target represents an increase of 48.43% from its latest reported closing price of 33.77.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Progyny is 1,058MM, an increase of 10.50%. The projected annual non-GAAP EPS is 0.39.
What is the Fund Sentiment?
There are 684 funds or institutions reporting positions in Progyny. This is an increase of 74 owner(s) or 12.13% in the last quarter. Average portfolio weight of all funds dedicated to PGNY is 0.47%, a decrease of 4.45%. Total shares owned by institutions decreased in the last three months by 2.45% to 110,576K shares. 
The put/call ratio of PGNY is 0.89, indicating a bullish outlook.
What are Other Shareholders Doing?
Tpg Gp A holds 9,250K shares representing 9.70% ownership of the company. No change in the last quarter.
KPCB XIII Associates holds 5,075K shares representing 5.32% ownership of the company. In it's prior filing, the firm reported owning 6,474K shares, representing a decrease of 27.57%. The firm decreased its portfolio allocation in PGNY by 2.97% over the last quarter.
Clearbridge Investments holds 4,047K shares representing 4.24% ownership of the company. In it's prior filing, the firm reported owning 4,117K shares, representing a decrease of 1.72%. The firm increased its portfolio allocation in PGNY by 13.71% over the last quarter.
Fred Alger Management holds 3,289K shares representing 3.45% ownership of the company. In it's prior filing, the firm reported owning 3,436K shares, representing a decrease of 4.45%. The firm increased its portfolio allocation in PGNY by 19.20% over the last quarter.
Jpmorgan Chase holds 2,669K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 2,573K shares, representing an increase of 3.59%. The firm increased its portfolio allocation in PGNY by 802.49% over the last quarter.
Progyny Background Information
(This description is provided by the company.)
Progyny is a leading fertility benefits management company in the US. The company is redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously benefit employers, patients, and physicians.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
